Medipharm Labs Revenue vs. EBITDA
| LABS Stock | CAD 0.07 0.01 7.14% |
Total Revenue | First Reported 2018-12-31 | Previous Quarter 9.8 M | Current Value 10.3 M | Quarterly Volatility 10.4 M |
For Medipharm Labs profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medipharm Labs to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medipharm Labs Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medipharm Labs's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medipharm Labs Corp over time as well as its relative position and ranking within its peers.
Medipharm |
Medipharm Labs Corp EBITDA vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Medipharm Labs's current stock value. Our valuation model uses many indicators to compare Medipharm Labs value to that of its competitors to determine the firm's financial worth. Medipharm Labs Corp is rated third overall in revenue category among its peers. It is currently regarded as number one stock in ebitda category among its peers . At this time, Medipharm Labs' Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Medipharm Labs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Medipharm Labs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Medipharm Revenue vs. Competition
Medipharm Labs Corp is rated third overall in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 245.42 Million. Medipharm Labs retains roughly 33.06 Million in revenue claiming about 13% of equities under Health Care industry.
Medipharm EBITDA vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Medipharm Labs |
| = | 33.06 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Medipharm Labs |
| = | (16.35 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Medipharm EBITDA Comparison
Medipharm Labs is currently under evaluation in ebitda category among its peers.
Medipharm Labs Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Medipharm Labs, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Medipharm Labs will eventually generate negative long term returns. The profitability progress is the general direction of Medipharm Labs' change in net profit over the period of time. It can combine multiple indicators of Medipharm Labs, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 29.5 M | 15.8 M | |
| Operating Income | -18.9 M | -19.8 M | |
| Net Loss | -13.1 M | -13.7 M | |
| Income Before Tax | -13.4 M | -14 M | |
| Net Loss | -27 M | -28.3 M | |
| Net Loss | -13.1 M | -13.7 M | |
| Total Other Income Expense Net | 5.5 M | 5.8 M | |
| Income Tax Expense | -276 K | -262.2 K | |
| Net Interest Income | 475 K | 498.8 K | |
| Interest Income | 840 K | 798 K | |
| Change To Netincome | 16.2 M | 8.1 M | |
| Net Loss | (0.04) | (0.04) | |
| Income Quality | 0.94 | 0.99 | |
| Net Income Per E B T | 0.98 | 0.70 |
Medipharm Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Medipharm Labs. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Medipharm Labs position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Medipharm Labs' important profitability drivers and their relationship over time.
Use Medipharm Labs in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medipharm Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medipharm Labs will appreciate offsetting losses from the drop in the long position's value.Medipharm Labs Pair Trading
Medipharm Labs Corp Pair Trading Analysis
The ability to find closely correlated positions to Medipharm Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medipharm Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medipharm Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medipharm Labs Corp to buy it.
The correlation of Medipharm Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medipharm Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medipharm Labs Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medipharm Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Medipharm Labs position
In addition to having Medipharm Labs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Global Macro ETFs Thematic Idea Now
Global Macro ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Global Macro ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Global Macro ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Medipharm Stock
To fully project Medipharm Labs' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Medipharm Labs Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Medipharm Labs' income statement, its balance sheet, and the statement of cash flows.